BioLife Solutions, Inc.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US09062W2044
USD
25.83
0.46 (1.81%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About BioLife Solutions, Inc. stock-summary
stock-summary
BioLife Solutions, Inc.
Pharmaceuticals & Biotechnology
BioLife Solutions, Inc. (BioLife) is engaged in the developing, manufacturing and marketing a portfolio of biopreservation tools and services for cells, tissues and organs, including clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management application for shippers. The Company's product offerings include hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs; generic blood stem cell freezing and cell thawing media products; custom product formulation and custom packaging services; cold chain logistics services incorporating precision thermal packaging products and cloud-hosted Web applications, and contract aseptic manufacturing formulation, fill and finish services of liquid media products. Its products include HypoThermosol FRS, CryoStor, BloodStor, Cell Thawing Media, PrepaStor and biologistex cold-chain management service.
Company Coordinates stock-summary
Company Details
3303 Monte Villa Pkwy Ste 310 , BOTHELL WA : 98021-6200
stock-summary
Tel: 1 425 40114001 425 4021400
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 64 Schemes (47.81%)

Foreign Institutions

Held by 73 Foreign Institutions (5.12%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Raymond Cohen
Independent Chairman of the Board
Mr. Michael Rice
President, Chief Executive Officer, Director
Mr. Andrew Hinson
Independent Director
Mr. Joseph Schick
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
25 Million
(Quarterly Results - Jun 2025)
Net Profit:
-16 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 1,256 Million (Small Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.20

stock-summary
Return on Equity

-5.76%

stock-summary
Price to Book

3.62